國家衛生研究院 NHRI:Item 3990099045/12724

NHRI > Institute of Biotechnology and Pharmaceutical Research > Chiung-Tong Chen > Periodical Articles > Item 3990099045/12724

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12724

Title:	A bubble bursting-mediated oral drug delivery system that enables concurrent delivery of lipophilic and hydrophilic chemotherapeutics for treating pancreatic tumors in rats
Authors:	Chen, KH;Miao, YB;Shang, CY;Huang, TY;Yu, YT;Yeh, CN;Song, HL;Chen, CT;Mi, FL;Lin, KJ;Sung, HW
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	The therapeutic outcome of pancreatic cancer remains unsatisfactory, despite many attempts to improve it. To address this challenge, an oral drug delivery system that spontaneously initiates an effervescent reaction to form gas-bubble carriers is proposed. These carriers concurrently deliver lipophilic paclitaxel (PTX) and hydrophilic gemcitabine (GEM) in the small intestine. The bursting of the bubbles promotes the intestinal absorption of the drugs. The antitumor efficacy of this proposed oral drug delivery system is evaluated in rats with experimentally created orthotopic pancreatic tumors. The combined administration of equivalent amounts of PTX and GEM via the intravenous (i.v.) route, which is clinically used for treating pancreatic cancer, serves as a control. Following oral administration, the lipophilic PTX is initially absorbed through the intestinal lymphatic system and then enters systemic circulation, whereas the hydrophilic GEM is directly taken up into the blood circulation, ultimately accumulating in the tumorous pancreatic tissues. A pharmacokinetic study reveals that the orally delivered formulation has none of the toxic side-effects that are associated with the i.v. injected formulation; changes the pharmacokinetic profiles of the drugs; and increases the bioavailability of PTX. The oral formulation has a greater impact than the i.v. formulation on tumor-specific stromal depletion, resulting in greater inhibition of tumor growth with no evidence of metastatic spread. As well as enhancing the therapeutic efficacy, this unique approach of oral chemotherapy has potential for use on outpatients, greatly improving their quality of life.
Date:	2020-10
Relation:	Biomaterials. 2020 Oct;255:Article number 120157.
Link to:	http://dx.doi.org/10.1016/j.biomaterials.2020.120157
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0142-9612&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000555693800012
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85086405351
Appears in Collections:	[Chiung-Tong Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB32535305.pdf		4288Kb	Adobe PDF	351	View/Open

Loading...